Keywords
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, characterized by relapsing or progressive neurological deficits. Despite advances in imaging and immunological markers, early diagnosis and prognosis prediction remain a clinical challenge. Recently, serum neurofilament light chain (NfL) has emerged as a highly promising biomarker for neuroaxonal damage, reflecting disease activity and progression in MS. As a non-invasive, blood-based marker, NfL offers potential utility in both initial diagnosis and longitudinal monitoring. Multiple sclerosis (MS) is one of the most disabling chronic autoimmune disorders of the central nervous system (CNS), affecting over 2.8 million people globally. Characterized by demyelination, axonal injury, and neurodegeneration, MS leads to cumulative disability, cognitive decline, and impaired quality of life. While magnetic resonance imaging (MRI) remains the gold standard for diagnosis and monitoring, it has limitations in assessing the underlying neuroaxonal damage, particularly in the progressive phases of the disease.
References
Andryev S. et al. Experience with the use of memantine in the treatment of cognitive disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
Asanova R. et al. Features of the treatment of patients with mental disorders and cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 545-550.
Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
Bo’Riyev B. et al. Features of clinical and psychopathological examination of young children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
Borisova Y. et al. Concomitant mental disorders and social functioning of adults with high-functioning autism/asperger syndrome //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 36-41.
Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in non-psychotic depressions in combination with chronic brain ischemia //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases in psychotherapeutic practice //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 898-903.
Novikov A. et al. Alcohol dependence and manifestation of autoagressive behavior in patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 413-419.
Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 240-244.
Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of therapeutic response in patients with paroxysmal schizophrenia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 385-391.
Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with somatized personality development //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 245-251.
Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 258-264.
Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia during prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 392-397.
Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the formation of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 186-191.
Prostyakova N. et al. Changes in the postpsychotic period after acute polymorphic disorder //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 356-360.
Prostyakova N. et al. Issues of professional ethics in the treatment and management of patients with late dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 158-165.
Prostyakova N. et al. Sadness and loss reactions as a risk of forming a relationship together //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 252-257.
Prostyakova N. et al. Strategy for early diagnosis with cardiovascular diseaseisomatized mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 166-172.
Rotanov A. et al. Comparative effectiveness of treatment of somatoform diseases in psychotherapeutic practice //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 267-272.
Rotanov A. et al. Diagnosis of depressive and suicidal spectrum disorders in students of a secondary special education institution //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 309-315.
Rotanov A. et al. Elderly epilepsy: neurophysiological aspects of non-psychotic mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 192-197.
Rotanov A. et al. Social, socio-cultural and behavioral risk factors for the spread of hiv infection //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 49-55.
Rotanov A. et al. Suicide and epidemiology and risk factors in oncological diseases //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 398-403.
Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 273-277.
Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 361-366.